Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876304 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
A Phase 1 study of Schizophrenia, sponsored by Taisho Pharmaceutical Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT00876304 is a Phase 1 study of Schizophrenia that has completed, run by Taisho Pharmaceutical Co.. The registered enrollment target is 39 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00876304, a Phase 1 study of Schizophrenia, has completed, sponsored by Taisho Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PF-04802540
Study Locations (1)
California
- Pfizer Investigational Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876304
The ClinicalTrials.gov registry entry for NCT00876304 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (82% lower). The listed sponsor is Taisho Pharmaceutical Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00876304 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00876304 about?
NCT00876304 is a clinical study titled "Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
What is the current status of trial NCT00876304?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2009-04. Estimated completion is 2009-09.
What conditions does trial NCT00876304 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00876304?
The interventions under investigation include: Placebo (DRUG), PF-04802540 (DRUG).
Who is sponsoring clinical trial NCT00876304?
This trial is sponsored by Taisho Pharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00876304 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.